Preclinical data that support this finding, suggesting that the downstream products of G-CSF-stimulated myeloid cells—such as IL-6 and IL-10—are largely responsible for the development of CRS upon T cell activation and expansion in vivo [37]. This evidence concerns the gene IL6 and congenital rubella syndrome.